Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27

Sovaldi (sofosbuvir) may have received even a higher NHI price if its cost-effectiveness had been assessed - some officials at the Ministry of Health, Labor and Welfare (MLHW) and the Central Social Insurance Medical Council (Chuikyo) said. Gilead Sciences K.K.’s...read more